According to the latest report by IMARC Group, titled “Endovascular Aneurysm Repair (EVAR) Market Report by Indication (Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm (TAA), Thoracoabdominal Aortic Aneurysm (TAAA), and Others), Product (Percutaneous EVAR, Fenestrated EVAR, Aortic Stents and TAA Grafts, and Others), Gender (Male, Female), Age (Pediatric, Adult, Geriatric), End-User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2024-2032”, the global endovascular aneurysm repair market reached a value of US$ 3.0 Billion in 2023. An endovascular aneurysm repair (EVAR) is a minimally invasive procedure employed to treat an aneurysm, which is a bulging, dilation or enlargement in the wall of an artery. This surgery involves making a small incision through which an endovascular graft is inserted inside the artery. The graft, inserted through the arteries in a long, narrow and flexible tube, which prevents blood from flowing into the aneurysm by expanding and sealing it off. Since open aneurysm repair requires surgically opening the chest or abdomen area of the patient, the rate of associated post-procedural complications is extremely high and often requires secondary re-intervention. However, EVAR is gaining widespread popularity among healthcare professionals as it results in short hospital stays and quicker recovery.
Global Endovascular Aneurysm Repair (EVAR) Market Trends:
A rise in the number of smokers, along with an increase in the consumption of alcohol, has significantly increased the risks of developing an aneurysm. This, along with the growing awareness regarding the benefits associated with the EVAR procedure, has provided a thrust to the market growth. Increasing geriatric population is further contributing to the market growth as older people are more prone to developing serious medical conditions. Additionally, the prevalence of high blood pressure increases the risk of heart, blood vessel and circulation problems, which can often lead to increased chances of developing aneurysms. Furthermore, enhanced research and development (R&D) activities have led to the advent of durable devices utilized for the procedure, which are expected to minimize the chances of failures, endoleaks and aneurysm rupture. Improved techniques and technological advancements have resulted in quicker and less-invasive procedures, which have reduced infection rates and improved patient outcomes. On account of the aforementioned factors, the market is expected to grow at a CAGR of 4.1% during 2024-2032.
Market Summary:
- Based on the indication, the market has been divided into Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm (TAA), Thoracoabdominal Aortic Aneurysm (TAAA) and others.
- On the basis of the product, the market has been categorized into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
- Based on the gender, the market has been bifurcated into male and female.
- On the basis of age, the market has been segregated into pediatric, adult and geriatric.
- Based on the end-user, the market has been classified into hospitals, clinics, ambulatory surgical centers and others.
- On the geographical front, the market has been divided into Asia Pacific, Europe, North America, Middle East and Africa, and Latin America.
- The competitive landscape of the market has also been analyzed, with the detailed profiles of the key players operating in the market. Some of these include Medtronic, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc, Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical, and Cardinal Health, Inc.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Indication, Product, Gender, Age, End-User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered |
Medtronic plc, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc., Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical Limited, and Cardinal Health, Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal